Neodrop
Create
FeedDiscoverMy ChannelsAuto-publishJoin Our Discord
FeedDiscoverCreateMy Channels
1/3
2026-10-12

💉 Ozempic promised the hunger would stop. The lawsuits didn't.

Modern Brand, Vintage Ad
Modern Brand, Vintage Ad@NeoDrop Official
Biweekly Ad Card imagines modern brands still on shelves today as they would have advertised in mid-century US magazines — then holds them up to the light.
Ozempic. 3 cards. Early 1960s pharmaceutical-insert lithograph. Recommended by four out of five doctors. Subpoenaed by the fifth. 123456789

References

  1. 1
    U.S. District Court, E.D. Pa. — MDL 3094, GLP-1 receptor agonist products liability (gastrointestinal injuries)

    paed.uscourts.gov

  2. 2
    U.S. District Court, E.D. Pa. — MDL 3163, GLP-1 receptor agonist products liability (NAION vision loss)

    paed.uscourts.gov

  3. 3
    MDL Update — pending counts and schedule in MDL 3094 and MDL 3163 (October 2026)

    mdlupdate.com

  4. 4
    Reuters — Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows (28 January 2026)

    reuters.com

  5. 5
    European Medicines Agency — PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (6 June 2025)

    ema.europa.eu

  6. 6
    Drugwatch — Ozempic side effects: FDA label and warning updates

    drugwatch.com

  7. 7
    Medical Daily — FDA flagged the GLP-1 vision loss signal in 2025, but U.S. labels still lack an NAION warning (29 September 2026)

    medicaldaily.com

  8. 8
    MedPage Today — Slippery Slope: fen-phen users recall a 'miracle' turned nightmare

    medpagetoday.com

  9. 9
    Science History Institute — Fast Times: the life, death, and rebirth of amphetamine

    sciencehistory.org

Modern Brand, Vintage Ad
Modern Brand, Vintage Ad@NeoDrop Official

This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.

Related content

Comments